Here's the dividend forecast out to 2030 for Sigma shares

This business could pay healthy dividends in the coming years…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Sigma Healthcare Ltd, owner of Chemist Warehouse, is projected to deliver long-term dividend growth, starting with a forecasted dividend of 4 cents per share in FY26, according to UBS.
  • UBS predicts Sigma's market share and sales will grow due to strategic advantages and expansion, with Chemist Warehouse leading the charge in Australia's health and beauty market.
  • By FY30, dividends could reach 8 cents per share, potentially doubling from FY26, driven by continued sales growth, profit margin improvements, and market expansion.

Owning Sigma Healthcare Ltd (ASX: SIG) shares could be a pleasing choice for long-term dividend income.

It may not have a reputation for being an ASX dividend share year, but if it's able to deliver year after year growth, then it could build a reputation for reliability.

There's no guarantee of how dividend payments are going to play out, but analysts are optimistic that the owner of the Chemist Warehouse, Amcal and Discount Drug Store brands could perform for investors. It has a presence in Australia and New Zealand, as well as countries including Ireland and the UAE.

Stethoscope with a piggy bank and hundred dollar notes.

Image source: Getty Images

FY26

The 2026 financial year is Sigma Healthcare's current financial year, so it's the most relevant for investors to know.

According to the forecast from the broker UBS, the owner of Chemist Warehouse is predicted to deliver an annual dividend per share of 4 cents.

UBS says that Chemist Warehouse, the key driver of Sigma Healthcare, is the leader in the attractive health and beauty market, which is growing at 6% per year, according to UBS' estimates.

Pleasingly, the broker expects Sigma Healthcare to continue gaining market share in the coming years. Due to leadership in price and range, regulatory advantages, compliance and its ability to fulfil online and in-store orders.

The sales growth, with both like-for-like (LFL) sales and store network expansion going well, is delivering operating leverage.

Chemist Warehouse LFL sales growth is expected by UBS to increase to 13.2% to in FY26. Its store count is forecast to grow at 33 per year because of franchisor support, acquisitions and international growth in existing and possibly new markets.

Combined with gross profit growth and the realisation of synergies after the merger, the company's sales should support operating profit (EBIT) margin growth, according to UBS. The broker predicts the EBIT margin can grow from 10.1% in FY26 and rise each year to 11.6% in FY30.

With all of that in mind, UBS predicts that owners of Sigma shares could receive an annual dividend per share of 4 cents in FY26.

FY27

Chemist Warehouse sales are expected to see LFL growth of 10.2% in FY27 and then high single digit growth through to the end of the decade thanks to an ageing population, health prioritisation, higher value medicines and greater category participation and spending per consumer in health and beauty.

This could help drive the company's annual dividend per share to 5 cents in FY27.

FY28

Sales, margins and profit could continue to rise in the 2028 financial year. This could help deliver a rise in the company's dividend per share to 6 cents.

FY29

The good times are predicted to continue into the 2029 financial year, giving the business even more economic firepower to increase the payout.

In FY29, UBS predicts the business could hike its payout again to 7 cents per share.

FY30

The final year of this series of projections could see the business decide to declare a dividend per share of 8 cents. If these forecasts prove correct, it would mean the dividend doubles between FY26 and FY30.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two happy pharmacists standing together in a pharmacy.
Healthcare Shares

Why Clarity Pharmaceuticals shares just fell 5% on today's announcement

Investors are balancing Clarity's long-term potential against near-term uncertainty.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Still down 40%, are Pro Medicus shares primed to break out?

Two major US contract wins in as many weeks could mark a turning point in sentiment.

Read more »

Happy healthcare workers in a lab.
Healthcare Shares

Telix share price leaping higher today on $3 billion US news

Investors are snapping up Telix shares on Monday following big US news.

Read more »

Four smiling young medics with arms crossed stand outside a hospital.
Healthcare Shares

Pro Medicus locks in 5-year, $37m Northwestern Medicine contract renewal

Pro Medicus has renewed its major contract with Northwestern Medicine, locking in higher fees and strengthened client ties for the…

Read more »

Rising healthcare ASX share price represented by doctor giving thumbs up
Healthcare Shares

Telix Pharmaceuticals announces US$40m Regeneron radiopharma deal

Telix Pharmaceuticals has announced a US$40m strategic collaboration with Regeneron for innovative radiopharmaceutical cancer therapies.

Read more »

Two health workers taking a break.
Healthcare Shares

It could be time to buy-low on this ASX small-cap stock according to brokers

This ASX healthcare stock keeps attracting positive ratings, with one broker now tipping a 268% rise.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »